Chugai Pharmaceutical Co., Ltd. and Roche Holding AG have announced additional results from the global Phase III COMMODORE 1 and 2 clinical trial program with crovalimab for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), on the basis of which the anti-C5 recycling monoclonal antibody has just been submitted for approval in Japan for this indication.
The data were also presented at the recent European Hematology Association (EHA) Hybrid Congress and will support crovalimab’s further global...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
